PFE Latest Headlines

Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), Pfizer (PFE) and Guardant Health (GH)

at www.tipranks.com (Tue, 28-Apr 11:20 AM)

BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update)

at seekingalpha.com (Tue, 28-Apr 10:36 AM)

BridgeBio gains after settlement in Pfizer Vyndamax patent dispute

at seekingalpha.com (Tue, 28-Apr 9:56 AM)

Pfizer Kept at Hold as Pipeline Uncertainty and LOE Risks Temper Upside, Price Target Cut to $26

at www.tipranks.com (Tue, 28-Apr 7:35 AM)

Pfizer Shareholders Reaffirm Leadership, Governance at 2026 Meeting

at www.tipranks.com (Mon, 27-Apr 7:15 PM)

Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Molina Healthcare (MOH) and Pfizer (PFE)

at www.tipranks.com (Mon, 27-Apr 9:30 AM)

Pfizer (PFE) Quietly Reloads Pipeline With Bold New Bets

at www.tipranks.com (Sat, 25-Apr 11:02 AM)

Earnings Scoreboard: 82% of S&P 500 early reporters top EPS estimates ahead of big tech wave

at seekingalpha.com (Sat, 25-Apr 9:30 AM)

BridgeBio gains amid report of settlement in Pfizer Vyndamax patent dispute

at seekingalpha.com (Fri, 24-Apr 1:58 PM)

Bristol, Pfizer's Eliquis becoming available on Mark Cuban Cost Plus Drug

at seekingalpha.com (Fri, 24-Apr 11:39 AM)

TACO Trade Joke No More? Trump's Art Of The Deal' Powers S&P 500's Steepest Highs And Lows

at www.benzinga.com (Fri, 24-Apr 7:31 AM)

Pfizer Advances PF-08653944 Liver Study, Reinforcing Long-Term Pipeline Visibility

at www.tipranks.com (Thu, 23-Apr 12:33 PM)

Pfizer’s Lyme Disease Vaccine Candidate Achieves 73% Efficacy in Key Phase 3 Trial – Regulatory Submissions Planned

Market Chameleon (Mon, 23-Mar 7:09 AM)

Pfizer’s Tilrekimig Shows Significant Efficacy in Atopic Dermatitis—Phase 3 Set to Accelerate

Market Chameleon (Mon, 9-Mar 7:12 AM)

PADCEV Plus Keytruda Shows Major Survival Benefit in Muscle-Invasive Bladder Cancer—A Potential Shift in Standard Care

Market Chameleon (Mon, 2-Mar 7:13 AM)

Pfizer Delivers Steady Growth Beyond COVID-19: 2025 Results Show 6% Revenue Increase in Core Portfolio and Strong Pipeline Momentum

Market Chameleon (Tue, 3-Feb 7:15 AM)